Media

Press Releases

Press Releases	Date
At ESMO 2026, Sun Pharma to Present Long-Term Follow-up Data on UNLOXCYT® (cosibelimab-ipdl) from One of the Largest Prospective Studies in Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)	25 October 2026
Sun Pharma Announces UNLOXCYT® (cosibelimab-ipdl) Has Received a Category 2A Preferred Designation in the Updated NCCN Guidelines for Locally Advanced Cutaneous Squamous Cell Carcinoma (laCSCC) Patients Who Are Not Candidates for Curative Surgery or Curative Radiation	20 October 2026
Sun Pharma Establishes Endowed Professorship at Mount Sinai to Advance Dermatologic Care	06 October 2026
New LEQSELVI® (deuruxolitinib) Two-Year Data in Severe Alopecia Areata Showed Sustained Efficacy and Safety at EADV Congress 2026	01 October 2026
Sun Pharma and LIB Therapeutics announce global licensing agreement for Lerodalcibep	September 28, 2026
NAAF-AHRS Guidelines	September 22, 2026
Sun Pharma and Christian Siriano Launch “Regrowth Restyled” to Inspire Adults Living with Severe Alopecia Areata	September 17, 2026
Sun Pharma Participates in White House Signing Ceremony Highlighting U.S. Medicines Pricing and Access Commitments	September 01, 2026
Sun Pharma to Present Pivotal Long-Term Follow-up Data on UNLOXCYT™ (cosibelimab-ipdl)	May 26, 2026
Sun Pharma Joins the Second Annual “Hats On” Challenge to Raise Awareness for Actinic Keratosis and Skin Cancer Prevention	May 18, 2026
Sun Pharmaceutical Industries, Inc. (Sun Pharma) Initiates Voluntary U.S. Nationwide Recall of DOXOrubicin Hydrochloride Liposome Injection 50mg/25 mL Due To Potential Presence of Glass Particles	May 13, 2026
Sun Pharma Highlights Advances in Alopecia Areata, Psoriasis, and Acne Research at 2026 AAD Annual Meeting	March 27, 2026
Sun Pharma Introduces SUNday, Highlighting the Everyday Realities of Skin Cancer Care	February 05, 2026
Sun Pharma Announces the Availability of UNLOXCYT™ (cosibelimab-ipdl) for Advanced Cutaneous Squamous Cell Carcinoma (aCSCC)	January 15, 2026

Press Releases	Date
FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma (aCSCC)	November 26, 2025
Sun Pharma Canada Inc. Acquires Commercial Rights to LEVULAN® KERASTICK®	November 12, 2025
Sun Pharma Announces Jeremy Allen as Vice President, Corporate Affairs for North America	October 22, 2025
Sun Pharma Announces Launch of LEQSELVI™ (deuruxolitinib) in the United States for the Treatment of Severe Alopecia Areata	July 14, 2025
Sun Pharma announces settlement with Incyte Corporation in litigation relating to LEQSELVI™	July 14, 2025
Sun Pharma announces the completion of its acquisition of Checkpoint Therapeutics, Inc.	May 30, 2025
Sun Pharma Announces FDA Approval of Next Generation BLU-U® Blue Light Photodynamic Therapy Illuminator for Actinic Keratosis	May 16, 2025
Music Icon Art Garfunkel Opens Up About His Experience with Psoriasis in Partnership with Sun Pharma	April 4, 2025
Sun Pharma to Acquire Checkpoint Therapeutics	March 9, 2025
ILUMYA® Found Effective for Treatment of Plaque Psoriasis Affecting Nails in Study Presented at 2025 AAD Conference	March 7, 2025

Press Releases	Date
Sun Pharma Presents LEQSELVI at the 2024 Fall Clinical Dermatology Conference	October 25, 2024
WINLEVI poster presentations at 2024 Fall Clinical Dermatology Conference	October 25, 2024
U.S. FDA Approves LEQSELVI™(deuruxolitinib), and Oral JAK Inhibitor for the Treatment of Severe Alopecia Areata	July 26, 2024
Sun Pharma Completes Taro Merger	June 24, 2024
Sun Pharma’s GL0034 (Utreglutide) Demonstrates Significant Weight Loss, Gluco-metabolic and Lipid Lowering Efficacy in Individuals with Obesity in Oral Presentation at the American Diabetes Association 84th Scientific Sessions	June 22, 2024
Press Release Results of the Phase III PIVOTAL trial of Nidlegy in melanoma to be presented at ASCO 2024	May 31, 2024
Taro Shareholders Approve Merger with Sun Pharma	May 23, 2024
Taro Announces Merger Agreement with Sun Pharma	January 18, 2024

Press Releases	Date
CEQUA® (cyclosporine ophthalmic solution) 0.09% Phase 4 Data Showed Sustained Improvement in Dry Eye Disease Signs and Symptoms in Patients Switched From Restasis® (cyclosporine ophthalmic emulsion) 0.05%	October 12, 2023
Sun Pharma Announces US FDA Filing Acceptance of New Drug Application For Deuruxolitinib	October 6, 2023
ADA GL0034 Data Release	June 24, 2023
Sun Pharma Announces Health Canada Approval of PRWINLEVI® (clascoterone cream 1%) for Topical Treatment of Acne	June 19, 2023
Late-Breaking Phase 3 Data at AAD 2023 Show Oral Investigational Medicine Deuruxolitinib Significantly Improved Scalp Hair Regrowth in Alopecia Areata	March 18, 2023
Sun Pharma completes acquisition of Concert Pharmaceuticals	March 6, 2023
Sun Pharma Announces US FDA Approval for Generic Lenalidomide Capsules	February 10, 2023
Sun Pharma Launches SEZABY™ (phenobarbital sodium) in the U.S. for Treatment of Neonatal Seizures	January 25, 2023
Sun Pharma to Acquire Concert Pharmaceuticals Inc	January 19, 2023

Press Releases	Date
SEZABY™ (phenobarbital sodium powder for injection) approved by US FDA for the treatment of neonatal seizures	November 18, 2022
Sun Pharma and SPARC enter into a license agreement for commercialization of phenobarbital for injection in the US	November 9, 2022
Sun Pharma Announces US FDA Approval for Generic Mesalamine Extended Release Capsules	May 12, 2022
Sun Pharma Presents Phase 3 Data for WINLEVI® (clascoterone) cream 1% for the Topical Treatment of Acne Vulgaris at the AAD Annual Meeting	March 25, 2022

Press Releases	Date
Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection	December 15, 2021
Sun Pharma Announces Availability of WINLEVI® (clascoterone) cream 1% in the U.S. for Topical Treatment of Acne Vulgaris	November 1, 2021
Sun Pharma and Cassiopea SpA Announce Signing of License and Supply Agreements for Winlevi® (clascoterone cream 1%) in US and Canada	July 26, 2021
Press Release Settlement of Patent Litigation for Generic Revlimid in US	June 22, 2021
Sun Pharma Launches Website for its Long Term Care Portfolio in the US	February 25, 2021

Press Releases	Date
Sun Pharma Announces 5-Year Sustained Efficacy and Safety Results for ILUMYA® in Patients with Moderate-to-Severe Plaque Psoriasis	October 21, 2020
Sun Pharma Announces Long-term Insights into the Clinical Use of ILUMYA TM	June 13, 2020
Sun Pharma Presents ODOMZO® and LEVULAN® KERASTICK® + BLU-U® Data, Offering Clinical Insights for Treating People with or at Risk of Skin Cancer	June 13, 2020
SPII Donates 2.5 Million Hydroxychloroquine Sulfate Tablets in the U.S. For Potential COVID-19 Treatment	March 27, 2020
Sun Pharma Introduces ABSORICA LD™ Capsules for Management of Severe Recalcitrant Nodular Acne in the U.S.	February 4, 2020

Press Releases	Date
Sun Pharma Launches Drizalma Sprinkle in the US	October 16, 2019
Sun Pharma Launches CEQUA for the Treatment of Dry Eye Disease in the US	October 14, 2019
Sun Pharma Presents Long-term Study Results that Show Significant Skin Clearance with ILUMYA	October 9, 2019
Sun Pharma Launches Ezallor Sprinkle (Rosuvastatin) in the U.S. for People Who Have Difficulty Swallowing	July 15, 2019
Late Breaking Phase 2 Data Showing Potential of ILUMYA for Psoriatic Arthritis	June 14, 2019
Sun Pharma Launches Ready-to-Infuse INFUGEM in the U.S.	April 8, 2019
ILUMYA 3 Year Data Demonstrates Sustained Skin Clearance in Patients with Moderate to Severe Plaque Psoriasis	March 1, 2019